Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Dryox Health S L currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner and 1 distinct art unit. The busiest examiner for the portfolio is STEINKE, SEAN JAMES, who is handling 1 pending office action. This indicates a very specific or early-stage prosecution effort for the company within the Biotechnology & Pharmaceuticals field.
Practitioners should focus exclusively on the preferences of STEINKE, SEAN JAMES to advance this case. The lack of multiple pending actions or examiners means there is no internal baseline for comparing prosecution success or examiner behavior. This company's strategy is currently tied to the resolution of this 1 pending office action. The outcome of this single case will define the current success of the patenting effort, making the interaction with the 1 distinct examiner the central element of the prosecution process. This singular focus within 1 art unit simplifies the administrative tracking but increases the impact of any single examiner's decision on the overall portfolio. The company must ensure that its responses are perfectly tailored to the expectations of this specific examiner to avoid further delays.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEINKE, SEAN JAMES | 1 | 12.5% | +42.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682856 | AN OIL-IN-WATER EMULSION GEL COMPRISING TIOTROPIUM BROMIDE | STEINKE, SEAN JAMES | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18682856 | AN OIL-IN-WATER EMULSION GEL COMPRISING TIOTROPIUM BROMIDE | STEINKE, SEAN JAMES | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18682856 | AN OIL-IN-WATER EMULSION GEL COMPRISING TIOTROPIUM BROMIDE | STEINKE, SEAN JAMES | 1619 | §103 | Final Rejection | — | Pending | Feb 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialDryox Health S L has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Sean James Steinke has the most, with 1 of Dryox Health S L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.